RNA Aptamer Inhibitors for AMPA Receptor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AMPA glutamate receptor inhibitors have limitations such as poor water solubility, lack of specificity, and inability to target functional forms of the receptor, hindering their effectiveness in treating neurological disorders like ALS and Alzheimer's disease.
Innovation Solution
Development of water-soluble nucleic acid ligands, specifically RNA aptamers, selected through SELEX and modified to enhance affinity and specificity, which inhibit glutamate binding to AMPA receptors, using a combination of SELEX and laser-pulse photolysis techniques to identify and characterize their inhibitory properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional AMPA receptor inhibitors are used, then some inhibitory activity is achieved, but water solubility is poor
Solution Approach 1:
The patent changes the chemical nature of the inhibitor from conventional small molecules to nucleic acid ligands (aptamers), fundamentally altering solubility parameters while maintaining inhibitory activity through sequence-specific binding to the AMPA receptor
Solution Approach 2:
The patent creates composite nucleic acid structures with specific secondary and tertiary folds that combine binding affinity with improved solubility characteristics, using engineered RNA or DNA sequences that form stable three-dimensional structures capable of high-affinity receptor interaction
2Reliability
If conventional AMPA receptor inhibitors are used, then some inhibition is achieved, but specificity to other receptors is lost
Solution Approach 1:
The patent designs aptamers with specific local structural features (secondary and tertiary folds) that are precisely tailored to recognize and bind only the AMPA receptor's unique binding site, creating highly specific interactions that do not cross-react with other glutamate receptors
Solution Approach 2:
The patent segments the binding interface into specific nucleic acid structural elements (loops, hairpins, junctions) that independently contribute to recognition of distinct features of the AMPA receptor, enabling high specificity through cumulative local interactions
3Measurement precision
If conventional inhibition assays are used, then inhibitor affinity is measured, but only desensitized receptor forms are targeted
Solution Approach 1:
The patent applies a fast kinetic assay method (laser-pulse photolysis) that releases glutamate on a microsecond timescale, allowing measurement of inhibitor binding to the functional, non-desensitized form of the receptor before desensitization can occur
Solution Approach 2:
The patent replaces conventional slow electrophysiological assays with a rapid photolytic activation system that uses light to trigger glutamate release, enabling time-resolved measurements of receptor activation and inhibitor binding kinetics on the microsecond-to-millisecond scale
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA aptamers demonstrate high affinity and specificity, effectively inhibiting AMPA receptor activity in the nanomolar range, outperforming existing inhibitors in terms of solubility and functional targeting, with potential therapeutic applications for neurodegenerative disorders.
Implementation Method 1
an improved method of identifying nucleic acids which specifically bind to and inhibit function of glutamate receptors. The method comprises first screening a nucleic acid library for a nucleic acid that binds to a glutamate receptor. A modified SELEX method was used to identify the nucleic acid ligands disclosed herein. Once a glutamate receptor-specific aptamer has been identified, the aptamer's ability to inhibit glutamate function is evaluated. By providing a cell that has been transfected to overexpress the glutamate receptor and measuring glutamate-induced whole-cell current in a single cell in the presence and absence of the nucleic acid identified by the SELEX method, a comparison of the measurement of whole cell current in the presence and absence of nucleic acid is informative of the aptamer's potential as a glutamate receptor inhibitor.
Data Source
AI summary
The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.